Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19

Author(s): Vivek P. Chavda*, Aayushi B. Patel, Lalitkumar K. Vora*, Rajeev K. Singla*, Priyal Shah, Vladimir N. Uversky and Vasso Apostolopoulos

Volume 28, Issue 46, 2022

Published on: 08 November, 2022

Page: [3658 - 3670] Pages: 13

DOI: 10.2174/1381612829666221024124848

Price: $65

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a major health concern worldwide and has evolved into different variants. SARS-CoV-2 possesses a spike glycoprotein on its envelope that binds to the angiotensin-converting enzyme 2 (ACE-2) receptor of the host cell via the receptor-binding domain (RBD) in the upper respiratory tract. Since the SARS-CoV-2 virus variants change the severity of the diesease and treatment scenarios, repurposing current medicines may provide a quick and appealing method with established safety features. The efficacy and safety of antiviral medicines against the coronavirus disease 2019 (COVID-19) have been investigated, and several of them are now undergoing clinical studies. Recently, it has been found that nitric oxide (NO) shows antiviral properties against SARS-CoV-2 and prevents the virus from binding to a host cell. In addition, NO is a well-known vasodilator and acts as an important coagulation mediator. With the fast-track development of COVID-19 treatments and vaccines, one avenue of research aimed at improving therapeutics is exploring different forms of drug delivery, including intranasal sprays and inhalation therapy. The nasal mucosa is more prone to be the site of infection as it is in more direct contact with the physical environment via air during inhalation and exhalation. Thus, the use of exogenous nasal NO therapy via the intranasal route displays a distinct advantage. Therefore, the objective of this review is to summarize the relevant actions of NO via the intranasal spray and inhalation delivery, its mechanism of action, and its use in the treatment of COVID-19.

« Previous Next »
[1]
Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Curr Res Pharmacol Drug Discov 2022; 3: 100086.
[2]
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines Natl Inst Heal 2020; 130. Available from: https://covid19treatmentguidelines.nih.gov/
[3]
Chavda VP, Feehan J, Apostolopoulos V. A veterinary vaccine for sars-cov-2: the first COVID-19 vaccine for animals. Vaccines (Basel) 2021; 9(6): 631.
[http://dx.doi.org/10.3390/vaccines9060631] [PMID: 34200587]
[4]
Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci 2020; 27(1): 104.
[http://dx.doi.org/10.1186/s12929-020-00695-2] [PMID: 33341119]
[5]
Carter LJ, Garner LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci 2020; 6(5): 591-605.
[http://dx.doi.org/10.1021/acscentsci.0c00501] [PMID: 32382657]
[6]
Kerbl R, Zepp F. Coronavirus disease 2019. Monatsschr Kinderheilkd 2021; 169(4): 308-11.
[http://dx.doi.org/10.1007/s00112-021-01158-0] [PMID: 33814618]
[7]
Chavda VP, Apostolopoulos V. Is booster dose strategy sufficient for omicron variant of sars-cov-2? Vaccines (Basel) 2022; 10(3): 367.
[http://dx.doi.org/10.3390/vaccines10030367] [PMID: 35334999]
[8]
Chavda VP, Apostolopoulos V. Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly? Maturitas 2022; 158: 78-81.
[http://dx.doi.org/10.1016/j.maturitas.2022.01.011] [PMID: 35241241]
[9]
Chavda VP, Apostolopoulos V. Global impact of delta plus variant and vaccination. Expert Rev Vaccines 2022; 21(5): 597-600.
[http://dx.doi.org/10.1080/14760584.2022.2044800]
[10]
Chavda VP, Hanuma Kumar Ghali EN, Yallapu MM, Apostolopoulos V. Therapeutics to tackle Omicron outbreak. Immunotherapy 2022; 14(11): 833-8.
[http://dx.doi.org/10.2217/imt-2022-0064] [PMID: 35678049]
[11]
Chavda VP, Patel AB, Vaghasiya DD. SARS‐CoV‐2 variants and vulnerability at the global level. J Med Virol 2022; 94(7): 2986-3005.
[http://dx.doi.org/10.1002/jmv.27717] [PMID: 35277864]
[12]
Chavda VP, Bezbaruah R, Athalye M, et al. Replicating viral vector-based vaccines for COVID-19: Potential avenue in vaccination arena. Viruses 2022; 14(4): 759.
[http://dx.doi.org/10.3390/v14040759] [PMID: 35458489]
[13]
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46(4): 586-90.
[http://dx.doi.org/10.1007/s00134-020-05985-9] [PMID: 32125455]
[14]
Chavda VP, Vora LK, Vihol DR. 2021; COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals. Clin Compl Med Pharmacol 2021; 1(1): 100004.
[http://dx.doi.org/10.1016/j.ccmp.2021.100004]
[15]
WHO. WHO Coronavirus (COVID-19) Dashboard 2022; 7. Available from: https://covid19.who.int/ (accessed September 5, 2022).
[16]
COVID-19 weekly epidemiological update 35. World Heal Organ 2021; 1-3.
[17]
World Health Organization. COVID-19 weekly epidemiological update 22. World Heal Organ 2021; 1-3.
[18]
Mazumder P, Kalamdhad A, Chaminda GGT, Kumar M. Coalescence of co-infection and antimicrobial resistance with SARS-CoV-2 infection: The blues of post-COVID-19 world. Case Stud Chem Environ Eng 2021; 3: 100093.
[http://dx.doi.org/10.1016/j.cscee.2021.100093]
[19]
Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. JAMA 2021; 326(1): 35-45.
[http://dx.doi.org/10.1001/jama.2021.8565] [PMID: 34037666]
[20]
Krishnan A, Gangadaran P, Chavda VP, et al. Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery. Exp Biol Med (Maywood) 2022; 247(14): 1244-52.
[http://dx.doi.org/10.1177/15353702221092984] [PMID: 35549570]
[21]
Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID‐19: A systematic review and current update. Acta Neurol Scand 2020; 142(1): 14-22.
[http://dx.doi.org/10.1111/ane.13266] [PMID: 32412088]
[22]
Riviello ED, Kiviri W, Twagirumugabe T, et al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition. Am J Respir Crit Care Med 2016; 193(1): 52-9.
[http://dx.doi.org/10.1164/rccm.201503-0584OC] [PMID: 26352116]
[23]
Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci 2020; 41(12): 3437-70.
[http://dx.doi.org/10.1007/s10072-020-04801-y]
[24]
Spinato G, Fabbris C, Polesel J, et al. Alterations in smell or taste in mildly symptomatic outpatients with sars-cov-2 infection. JAMA 2020; 323(20): 2089-90.
[http://dx.doi.org/10.1001/jama.2020.6771] [PMID: 32320008]
[25]
Agresti N, Lalezari JP, Amodeo PP, et al. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. J Transl Autoimmun 2021; 4: 100083.
[http://dx.doi.org/10.1016/j.jtauto.2021.100083] [PMID: 33521616]
[26]
Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force. Eur Respir J 2020; 56(6): 2002197.
[http://dx.doi.org/10.1183/13993003.02197-2020] [PMID: 32817258]
[27]
Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 2022; 12(4): 735-57.
[http://dx.doi.org/10.1007/s13346-020-00891-5] [PMID: 33491126]
[28]
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45(3): 486-552.
[http://dx.doi.org/10.1097/CCM.0000000000002255] [PMID: 28098591]
[29]
Chavda VP, Gajjar N, Shah N, Dave DJ. Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. Europ J Med Chem Rep 2021; 3: 100013.
[http://dx.doi.org/10.1016/j.ejmcr.2021.100013]
[30]
Olson KR, Donald JA, Dombkowski RA, Perry SF. Evolutionary and comparative aspects of nitric oxide, carbon monoxide and hydrogen sulfide. Respir Physiol Neurobiol 2012; 184(2): 117-29.
[http://dx.doi.org/10.1016/j.resp.2012.04.004] [PMID: 22546339]
[31]
Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ 2020; 370: m3379.
[http://dx.doi.org/10.1136/bmj.m3379] [PMID: 32887691]
[32]
Chavda VP, Apostolopoulos V. Mucormycosis-An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19. Maturitas 2021; 154: 58-61.
[http://dx.doi.org/10.1016/j.maturitas.2021.07.009] [PMID: 34364730]
[33]
Chavda VP, Sonak SS, Munshi NK, Dhamade PN. Pseudoscience and fraudulent products for COVID-19 management. Environ Sci Pollut Res Int 2022; 29(42): 62887-912.
[http://dx.doi.org/10.1007/s11356-022-21967-4] [PMID: 35836045]
[34]
Chakraborty R, Parvez S. COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol 2020; 180: 114184.
[http://dx.doi.org/10.1016/j.bcp.2020.114184] [PMID: 32739342]
[35]
Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov Today 2021; 26(11): 2619-36.
[http://dx.doi.org/10.1016/j.drudis.2021.07.021] [PMID: 34332100]
[36]
Winchester S, John S, Jabbar K, John I. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect 2021; 83(2): 237-79.
[37]
Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev Vaccines 2021; 20(12): 1549-60.
[http://dx.doi.org/10.1080/14760584.2021.1987223] [PMID: 34582298]
[38]
Chavda VP, Hossain MK, Beladiya J, Apostolopoulos V. Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena. Biologics 2021; 1(3): 337-56.
[http://dx.doi.org/10.3390/biologics1030020]
[39]
Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020; 10: 587269.
[http://dx.doi.org/10.3389/fcimb.2020.587269] [PMID: 33324574]
[40]
Kim H. Outbreak of novel coronavirus (COVID-19): What is the role of radiologists? Eur Radiol 2020; 30(6): 3266-7.
[http://dx.doi.org/10.1007/s00330-020-06748-2] [PMID: 32072255]
[41]
Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J 2021; 23(1): 14.
[http://dx.doi.org/10.1208/s12248-020-00532-2] [PMID: 33400058]
[42]
Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. BMJ 2021; 97(1147): 312-20.
[http://dx.doi.org/10.1136/postgradmedj-2020-138577]
[43]
Tarighi P, Eftekhari S, Chizari M, Sabernavaei M, Jafari D, Mirzabeigi P. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol 2021; 895: 173890.
[http://dx.doi.org/10.1016/j.ejphar.2021.173890] [PMID: 33482181]
[44]
Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, et al. Azithromycin in the treatment of COVID-19: A review. Expert Rev Anti Infect Ther 2021; 19(2): 147-63.
[http://dx.doi.org/10.1080/14787210.2020.1813024] [PMID: 32853038]
[45]
Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID‐19. Clin Pharmacol Ther 2020; 108(2): 201-11.
[http://dx.doi.org/10.1002/cpt.1857] [PMID: 32302411]
[46]
Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology 2020; 551: 1-9.
[http://dx.doi.org/10.1016/j.virol.2020.08.011] [PMID: 33010669]
[47]
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med 2021; 384(8): 693-704.
[http://dx.doi.org/10.1056/NEJMoa2021436] [PMID: 32678530]
[48]
Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses 2021; 64(8): 798-808.
[http://dx.doi.org/10.1111/myc.13256] [PMID: 33590551]
[49]
Kow CS, Hasan SS. Dexamethasone or hydrocortisone in COVID-19? Cleve Clin J Med 2020; 87(12): 715.
[http://dx.doi.org/10.3949/ccjm.87c.12005] [PMID: 33229384]
[50]
Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021; 102: 501-8.
[http://dx.doi.org/10.1016/j.ijid.2020.10.069] [PMID: 33130203]
[51]
Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020; 76(4): 370-6.
[http://dx.doi.org/10.1016/j.mjafi.2020.08.004] [PMID: 32895599]
[52]
Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020; 72(6): 1479-508.
[http://dx.doi.org/10.1007/s43440-020-00155-6] [PMID: 32889701]
[53]
Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review. J Med Virol 2021; 93(1): 275-99.
[http://dx.doi.org/10.1002/jmv.26254] [PMID: 32617987]
[54]
Lundberg JO, Weitzberg E, Gladwin MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7(2): 156-67.
[http://dx.doi.org/10.1038/nrd2466] [PMID: 18167491]
[55]
Mortaz E, Tabarsi P, Varahram M, Folkerts G, Adcock IM. The immune response and immunopathology of COVID-19. Front Immunol 2020; 11: 2037.
[http://dx.doi.org/10.3389/fimmu.2020.02037] [PMID: 32983152]
[56]
Udupa A, Leverenz D, Balevic SJ, Sadun RE, Tarrant TK, Rogers JL. Hydroxychloroquine and COVID-19: A rheumatologist’s take on the lessons learned. Curr Allergy Asthma Rep 2021; 21(1): 5.
[http://dx.doi.org/10.1007/s11882-020-00983-9] [PMID: 33475900]
[57]
Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol 2020; 883: 173372.
[http://dx.doi.org/10.1016/j.ejphar.2020.173372] [PMID: 32682787]
[58]
Mikuls TR, Johnson SR, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the covid‐19 pandemic: version 1. Arthritis Rheumatol 2020; 72(8): 1241-51.
[http://dx.doi.org/10.1002/art.41301] [PMID: 32349183]
[59]
Lamb YN. Nirmatrelvir plus ritonavir: First approval. Drugs 2022; 82(5): 585-91.
[http://dx.doi.org/10.1007/s40265-022-01692-5] [PMID: 35305258]
[60]
Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr 2021; 15(6): 102329.
[http://dx.doi.org/10.1016/j.dsx.2021.102329] [PMID: 34742052]
[61]
Heo YA. Sotrovimab: First approval. Drugs 2022; 82(4): 477-84.
[http://dx.doi.org/10.1007/s40265-022-01690-7] [PMID: 35286623]
[62]
Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 MedRxiv 2022; 2022.03.
[http://dx.doi.org/10.1101/2022.03.10.22272100]
[63]
Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of covid-19. N Engl J Med 2022; 386(23): 2188-200.
[http://dx.doi.org/10.1056/NEJMoa2116620] [PMID: 35443106]
[64]
Tixagevimab and Cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. JAMA 2022; 327(4): 384-5.
[http://dx.doi.org/10.1001/jama.2021.24931] [PMID: 35076671]
[65]
Fang W, Jiang J, Su L, et al. The role of NO in COVID-19 and potential therapeutic strategies. Free Radic Biol Med 2021; 163: 153-62.
[http://dx.doi.org/10.1016/j.freeradbiomed.2020.12.008] [PMID: 33347987]
[66]
Dominic P, Ahmad J, Bhandari R, et al. 2021; Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19. Redox Biol 2021; 43: 101982.
[http://dx.doi.org/10.1016/j.redox.2021.101982] [PMID: 34020311]
[67]
Ghalayini IF. Nitric oxide–cyclic GMP pathway with some emphasis on cavernosal contractility. Int J Impot Res 2004; 16(6): 459-69.
[http://dx.doi.org/10.1038/sj.ijir.3901256] [PMID: 15229623]
[68]
Immediate implementation of appropriate infection prevention and control measures. In.Clinical management of COVID-19: Living guideline, 23 June 2022. Geneva: World Health Organization 2022; pp. 19-21.
[69]
Wu Y, Li Z, Zhao YS, Huang YY, Jiang MY, Luo HB. Therapeutic targets and potential agents for the treatment of COVID‐19. Med Res Rev 2021; 41(3): 1775-97.
[http://dx.doi.org/10.1002/med.21776] [PMID: 33393116]
[70]
Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. Proc Natl Acad Sci 2018; 115(23): 5839-48.
[http://dx.doi.org/10.1073/pnas.1804932115]
[71]
Gladwin MT, Grubina R, Doyle MP. The new chemical biology of nitrite reactions with hemoglobin: R-state catalysis, oxidative denitrosylation, and nitrite reductase/anhydrase. Acc Chem Res 2009; 42(1): 157-67.
[http://dx.doi.org/10.1021/ar800089j] [PMID: 18783254]
[72]
Prakash A, Kaur S, Kaur C, et al. Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review. Indian J Pharmacol 2021; 53(3): 236-43.
[http://dx.doi.org/10.4103/ijp.ijp_382_21] [PMID: 34169911]
[73]
Backer V, Sjöbring U, Sonne J, et al. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19. Lancet Reg Heal - Eur 2021; 4: 100084.
[74]
Lundberg JON, Weitzberg E. Nasal nitric oxide in man. Thorax 1999; 54(10): 947-52.
[http://dx.doi.org/10.1136/thx.54.10.947] [PMID: 10491460]
[75]
Martel J, Ko YF, Young JD, Ojcius DM. Could nasal nitric oxide help to mitigate the severity of COVID-19? Microbes Infect 2020; 22(4-5): 168-71.
[http://dx.doi.org/10.1016/j.micinf.2020.05.002] [PMID: 32387333]
[76]
Croen KD. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993; 91(6): 2446-52.
[http://dx.doi.org/10.1172/JCI116479] [PMID: 8390481]
[77]
Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994; 24(4): 982-8.
[http://dx.doi.org/10.1016/0735-1097(94)90859-1]
[78]
Walsh BK. Inhaled pulmonary vasodilators in the neonatal and pediatric ICU. Respir Care 2020; 65(10): 1611-23.
[http://dx.doi.org/10.4187/respcare.08265] [PMID: 32973104]
[79]
Barnes M, Brisbois EJ. Clinical use of inhaled nitric oxide: Local and systemic applications. Free Radic Biol Med 2020; 152: 422-31.
[http://dx.doi.org/10.1016/j.freeradbiomed.2019.11.029] [PMID: 31785330]
[80]
Long R, Jones R, Talbot J, et al. Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2005; 49(3): 1209-12.
[http://dx.doi.org/10.1128/AAC.49.3.1209-1212.2005] [PMID: 15728930]
[81]
Cannistrà M, Ruggiero M, Zullo A, et al. Hepatic ischemia reperfusion injury: A systematic review of literature and the role of current drugs and biomarkers. Int J Surg 2016; 33 (Suppl. 1): S57-70.
[http://dx.doi.org/10.1016/j.ijsu.2016.05.050] [PMID: 27255130]
[82]
Harris CC, Hollstein M. The New England Journal of Medicine Downloaded from nejm.org at Universitaetsbibliothek Wuerzburg on July 18, 2013. For personal use only. No other uses without permission. Copyright© 1993 Massachusetts Medical Society. All rights reserved. N Engl J Med 1993; 329: 1318-27.
[http://dx.doi.org/10.1056/NEJM199310283291807] [PMID: 8413413]
[83]
Durán WN, Breslin JW, Sánchez FA. The NO cascade, eNOS location, and microvascular permeability. Cardiovasc Res 2010; 87(2): 254-61.
[http://dx.doi.org/10.1093/cvr/cvq139] [PMID: 20462865]
[84]
Di Lorenzo A, Lin MI, Murata T, et al. eNOS derived nitric oxide regulates endothelial barrier function via VE cadherin and Rho GTPases. J Cell Sci 2013; 126(Pt 24): jcs.115972.
[http://dx.doi.org/10.1242/jcs.115972] [PMID: 24046447]
[85]
Cau SBA, Carneiro FS, Tostes RC. Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. Front Physiol 2012; 3: 218.
[http://dx.doi.org/10.3389/fphys.2012.00218] [PMID: 22737132]
[86]
Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009; 229(1): 173-91.
[http://dx.doi.org/10.1111/j.1600-065X.2009.00766.x] [PMID: 19426222]
[87]
Dong M, Zhang J, Ma X, Tan J, Chen L. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect , the company’s public news and information 2020. Available at: https://www.elsevier.com/connect/coronavirus-information-center
[88]
Miller C, Miller M, McMullin B, et al. A phase I clinical study of inhaled nitric oxide in healthy adults. J Cyst Fibros 2012; 11(4): 324-31.
[http://dx.doi.org/10.1016/j.jcf.2012.01.003] [PMID: 22520076]
[89]
Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res 2020; 126(10): 1456-74.
[http://dx.doi.org/10.1161/CIRCRESAHA.120.317015] [PMID: 32264791]
[90]
Kapil V, Khambata RS, Jones DA, et al. The noncanonical pathway for in vivo nitric oxide generation: The nitrate-nitrite-nitric oxide pathway. Pharmacol Rev 2020; 72(3): 692-766.
[http://dx.doi.org/10.1124/pr.120.019240] [PMID: 32576603]
[91]
Kamenshchikov NO, Berra L, Carroll RW. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines 2022; 10(2): 369.
[http://dx.doi.org/10.3390/biomedicines10020369] [PMID: 35203578]
[92]
Chavda VP, Kapadia C, Soni S, et al. A global picture: therapeutic perspectives for COVID-19. Immunotherapy 2022; 14(5): 351-71.
[http://dx.doi.org/10.2217/imt-2021-0168] [PMID: 35187954]
[93]
Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 2022; 198: 105252.
[http://dx.doi.org/10.1016/j.antiviral.2022.105252] [PMID: 35085683]
[94]
Chavda VP, Prajapati R, Lathigara D, et al. Therapeutic monoclonal antibodies for COVID-19 management: An update. Expert Opin Biol Ther 2022; 22(6): 763-80.
[http://dx.doi.org/10.1080/14712598.2022.2078160] [PMID: 35604379]
[95]
More R, Kingsland J, Sanfins A, Images G. COVID-19 : Nitric oxide shows promise as antiviral treatment 2021; 1-14.
[96]
Akaberi D, Krambrich J, Ling J, et al. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biol 2020; 37: 101734.
[http://dx.doi.org/10.1016/j.redox.2020.101734] [PMID: 33007504]
[97]
Lancaster JR Jr. Nitric oxide: a brief overview of chemical and physical properties relevant to therapeutic applications. Future Sci OA 2015; 1(1): fso.15.59.
[http://dx.doi.org/10.4155/fso.15.59] [PMID: 28031866]
[98]
Åkerström S, Gunalan V, Keng CT, Tan YJ, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected. Virology 2009; 395(1): 1-9.
[http://dx.doi.org/10.1016/j.virol.2009.09.007] [PMID: 19800091]
[99]
Regev-Shoshani G, Vimalanathan S, McMullin B, Road J, Av-Gay Y, Miller C. Gaseous nitric oxide reduces influenza infectivity in vitro. Nitric Oxide 2013; 31: 48-53.
[http://dx.doi.org/10.1016/j.niox.2013.03.007] [PMID: 23562771]
[100]
Tousoulis D, Kampoli AM, Tentolouris Nikolaos Papageorgiou C, Stefanadis C, Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012; 10(1): 4-18.
[http://dx.doi.org/10.2174/157016112798829760] [PMID: 22112350]
[101]
Budinger GRS, Mutlu GM. Balancing the risks and benefits of oxygen therapy in critically III adults. Chest 2013; 143(4): 1151-62.
[http://dx.doi.org/10.1378/chest.12-1215] [PMID: 23546490]
[102]
Tamminen PJ, Kerimov DM, Viskari H, Aittoniemi J, Syrjänen J, Lehtimäki L. Nasal nitric oxide is decreased in acute mild COVID-19 and related to viral load. J Breath Res 2022; 16(4): 046003.
[http://dx.doi.org/10.1088/1752-7163/ac7d6a] [PMID: 35772381]
[103]
Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med 2020; 9(5): 1417.
[http://dx.doi.org/10.3390/jcm9051417] [PMID: 32403217]
[104]
Kobayashi J, Murata I. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. Ann Intensive Care 2020; 10(1): 61.
[http://dx.doi.org/10.1186/s13613-020-00681-9] [PMID: 32436029]
[105]
Feng W-X, Yang Y, Wen J, Liu Y-X, Liu L, Feng C. Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension. ESC Heart Fail 2021; 8: 714-8.
[106]
Tandon M, Wu W, Moore K, et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial. Lancet Regional Health - Southeast Asia 2022; 3: 100036.
[http://dx.doi.org/10.1016/j.lansea.2022.100036] [PMID: 35784831]
[107]
Ferrari M, Protti A. Nitric oxide in COVID-19: Too little of a good thing? EBioMedicine 2022; 77: 103925.
[http://dx.doi.org/10.1016/j.ebiom.2022.103925] [PMID: 35278744]
[108]
Moni M, Madathil T, Sathyapalan DT, et al. Clinical efficacy of inhaled nitric oxide in preventing the progression of moderate to severe COVID-19 and its correlation to viral clearance: Results of a pilot study. Infect Microbes Dis 2022; 4: 26-33.https://journals.lww.com/imd/Fulltext/2022/03000/Clinical_Efficacy_of_Inhaled_Nitric_Oxide_in.5.aspx
[109]
Valsecchi C, Winterton D, Safaee Fakhr B, et al. Collaborators, high-dose inhaled nitric oxide for the treatment of spontaneously breathing pregnant patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Obstet Gynecol 2022; 140(2): 195-203.https://journals.lww.com/greenjournal/Fulltext/9900/High_Dose_Inhaled_Nitric_Oxide_for_the_Treatment.526.aspx
[110]
Poonam PBH, Koscik R, Nguyen T, Rikhi S, Lin HM. Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19. PLoS One 2022; 17(6): e0270646.
[http://dx.doi.org/10.1371/journal.pone.0270646] [PMID: 35759496]
[111]
Parikh R, Wilson C, Weinberg J, Gavin D, Murphy J, Reardon CC. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther Adv Respir Dis 2020; 14.
[http://dx.doi.org/10.1177/1753466620933510] [PMID: 32539647]
[112]
Safaee Fakhr B, Di Fenza R, Gianni S, et al. 2021; Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide 2021; 116: 7-13.
[http://dx.doi.org/10.1016/j.niox.2021.08.003] [PMID: 34400339]
[113]
Quintana DS, Guastella AJ, Westlye LT, Andreassen OA. The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry 2016; 21(1): 29-38.
[http://dx.doi.org/10.1038/mp.2015.166] [PMID: 26552590]
[114]
Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 2018; 143: 155-70.
[http://dx.doi.org/10.1016/j.brainresbull.2018.10.009] [PMID: 30449731]
[115]
Åkerström S, Mousavi-Jazi M, Klingström J, Leijon M, Lundkvist Å, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005; 79(3): 1966-9.
[http://dx.doi.org/10.1128/JVI.79.3.1966-1969.2005] [PMID: 15650225]
[116]
Lei C, Su B, Dong H, et al. Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2) MedRxiv 2020; 2020.03.09.20033530.
[http://dx.doi.org/10.1101/2020.03.09.20033530]
[117]
Swathi Krishna S, Thennavan A, Kanthlal SK. Dietary foods containing nitric oxide donors can be early curators of SARS-CoV-2 infection: A possible role in the immune system. J Food Biochem 2021; e13884.
[118]
Longobardo A, Montanari C, Shulman R, Benhalim S, Singer M, Arulkumaran N. Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome. Br J Anaesth 2021; 126(1): e44-6.
[http://dx.doi.org/10.1016/j.bja.2020.10.011] [PMID: 33138964]
[119]
Sanotize Research and Development corp. Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection (NOCOVID). ClinicalTrialsGov 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04337918 (Accessed on: April 25, 2021).
[120]
Parkins K. SaNOtize’s “revolutionary” COVID-19 nasal spray bolstered by Phase II trial data. Clin Trials Arena 2021. Available from: https://www.clinicaltrialsarena.com/news/sanotize-nasal-spray-reduces-covid-19-viral-load-uk-clinical-trail/ (accessed April 25, 2021).
[121]
Tucker C, Tucker L, Brown K. The intranasal route as an alternative method of medication administration. Crit Care Nurse 2018; 38(5): 26-31.
[http://dx.doi.org/10.4037/ccn2018836] [PMID: 30275061]
[122]
Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci 2001; 59(1): 5-16.
[http://dx.doi.org/10.1093/toxsci/59.1.5] [PMID: 11134540]
[123]
SaNOtize. UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19 BusinessWire 2021. Available from: https://www.businesswire.com/news/home/20210315005197/en/UK-Clinical-Trial-Confirms-SaNOtize’s-Breakthrough-Treatment-for-COVID-19
[124]
LungFit® PH PMA. Revolutionizing Nitric Oxide Therapy. Beyondair 2021. Available from: https://www.beyondair.net/ (Accessed on: April 25, 2021).
[125]
Winchester S, John S, Jabbar K, John I. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. J Infect 2021; 83(2): 237-79.
[126]
U.S Food & Drug.. Vero Biotech Recalls GENOSYL DS ; Nitric Oxide Delivery System Due to Software Error Available from: https://www.fda.gov/medical-devices/medical-device-recalls/vero-biotech-recalls-genosyl-ds-nitric-oxide-delivery-system-due-software-error
[127]
Shmuel K, Dalia M, Tair L, Yaakov N. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey. Expert Rev Anti Infect Ther 2021; 19(10): 1325-30.
[http://dx.doi.org/10.1080/14787210.2021.1908127] [PMID: 33759682]
[128]
Hull D, Rennie P, Noronha A, et al. Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold. Acta Otorhinolaryngol Ital 2007; 27: 73-7.
[129]
VERO Biotech, Technology. 2020. Available from: https://www.vero-biotech.com/technology/ (Accessed on: April 25, 2021).
[130]
Viraleze ViralezeTM antiviral nasal spray 2021; 1-3. Available from: https://viraleze.co/
[131]
BioSpectrum. Australia’s Starpharma’s launches COVID-19 antiviral nasal spray VIRALEZE in the UK Available from: https://www.biospectrumasia.com/news/90/17890/australias-starpharmas-launches-covid-19-antiviral-nasal-spray-viraleze-in-the-uk.html
[132]
WHO. Viralezetm targets the area in the nasal cavity where respiratory viruses that cause colds, flu and more severe respiratory illness, such as covid-19, first attach and start to multiply Available from: https://www.emro.who.int/health-topics/corona-virus/about-covid-19.html
[133]
Mallinckrodt Pharmaceuticals INOmax® (nitric oxide) Available from: https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=25621
[134]
Syndrome D. Mallinckrodt supports investigator-initiated study at massachusetts general hospital to assess effectiveness of inhaled nitric oxide in patients with severe acute respiratory. Distress Syndrome Due to COVID-19. Mallinckrodt Pharmaceuticals 2020; 30. Available from: http://www.mallinckrodt.com/about.news-and-media/news-detail/?Id=26721
[135]
Ards C. BRIEF-Mallinckrodt evaluates potential role for inhaled nitric oxide to treat covid-19 associated lung complications Available from: reuters.com/article/brief-mallinckrodt-evaluates-potential-r-idINFWN2B505C
[136]
Lung CA. Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide Scientific. Governmental and Regulatory Agencies 2021; 1-4.
[137]
Corp D. Nitric Oxide Nasal Spray (NONS). Clinical Trial 2021; 1-5.
[138]
Massachusetts General Hospital. Nitric oxide gas inhalation in severe acute respiratory syndrome in COVID-19 (NOSARSCOVID) Available from: https://clinicaltrials.gov/ct2/show/NCT04306393
[139]
Robbins RA, Grisham MB. Nitric oxide. Int J Biochem Cell Biol 1997; 29(6): 857-60.
[http://dx.doi.org/10.1016/S1357-2725(96)00167-7] [PMID: 9304799]
[140]
Benedetto M, Romano R, Baca G, et al. Inhaled nitric oxide in cardiac surgery: Evidence or tradition? Nitric Oxide 2015; 49: 67-79.
[http://dx.doi.org/10.1016/j.niox.2015.06.002] [PMID: 26186889]
[141]
Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Libr 2016; 2018(12): CD002787.
[http://dx.doi.org/10.1002/14651858.CD002787.pub3] [PMID: 27347773]
[142]
Srivastava S, Garg I, Hembrom AA, Kumar B. Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity. Virusdisease 2021; 32(3): 589-94.
[http://dx.doi.org/10.1007/s13337-021-00702-6] [PMID: 34099981]
[143]
CDC. Medical management guidelines for nitrogen oxides. ATSDR Agency Toxic Subst Dis Regist 2022. Available from: https://wwwn.cdc.gov/TSP/MMG/MMGDetails.aspx?mmgid=394&toxid=69 (accessed September 3, 2022).
[144]
Wong VWC, Lerner E. Nitric oxide inhibition strategies. Future Sci OA 2015; 1(1): fso.15.35.
[http://dx.doi.org/10.4155/fso.15.35] [PMID: 26634146]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy